Two Shot Same Day Exception Rules for COVID-19
For COVID-19 shots administered:
This page specifies the COVID-19 logic implemented by ICE for recommendations before September 12, 2023.
For COVID-19 logic for recommendations as of September 12, 2023 onwards, see COVID-19 Vaccine Group - September 2023 Onwards.
Two Shot Same Day Exception Rules for COVID-19
For COVID-19 shots administered:
- before 10/25/2021, the Duplicate Shot, Same Day rules do NOT apply because absolute minimum intervals between dose 1 and dose 2 = 0 days (before 10/25/2021) in both the Pfizer COVID-19 2-dose series and Moderna COVID-19 2-dose series.
- on or after 10/25/2021, the Duplicate Shot, Same Day rules apply because absolute minimum intervals between dose 1 and dose 2 > 0 days (on or after 10/25/2021) in both the Pfizer COVID-19 2-dose series and Moderna COVID-19 2-dose series.
...
Panel | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
|
COVID-19 Vaccine Group Evaluation and Forecasting Rules
General Rules for COVID-19
General rules are not series-specific; general rules apply to the entire vaccine group.
Panel | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||
Anchor |
| ||||||||||||||
Anchor | SeriesCompletionSpecialRule | SeriesCompletionSpecialRule | Series Completion Special Rule
Anchor | ||||
---|---|---|---|---|
|
- Once a patient completes: If a patient completes a
- the Pfizer COVID-19 Series,
- and is < 5 years old:
- if the execution date is < 3/17/2023, the recommendation is Not Recommended and the reason code is COMPLETE.
- if the execution date is >= 3/17/2023 and a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520) has not been administered, recommend a dose of COVID-19 at the vaccine group level and recommended interval (8 weeks) or on 3/17/2023, whichever date is latest, along with recommendation reasons ADMINISTER_COVID19_BIVALENT_VACCINE and SUPPLEMENTAL_TEXT and Descriptive Text: "Patients who previously completed a 3-dose monovalent primary series are recommended to receive 1 bivalent booster dose, at least 8 weeks after completion of the monovalent primary series.
- and is >= 5 years old:
- if the execution date is >= 4/19/2023:
- See Section "Rules for Booster Dose", Bullet Point: "After completion of the Pfizer COVID-19 Series, the execution date is >= 3/17/2023, and the patient is < 5 years of age"
- if the execution date is >= 4/19/2023:
- if the execution date is < 9/2/2022:
- and is >= 5 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (
- 5 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.
- and receives an additional dose1, the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and receives a booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.
if the execution date is >= 9/2/2022 and is < 4/19/2023:
and is >=
5 years old,
recommend a booster dose of COVID-19 (at vaccine group level)
at recommended interval (
8 weeks) or at recommended age (
5 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE
- and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and receives an additional dose1, the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and receives a booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.
- and is >= 12 years old
.
See “Rules for Booster Dose” for booster dose recommendations for the Pfizer COVID-19 Series.
- and is < 5 years old:
- the Mixed Product or Moderna COVID-19 Series,
- if the execution date is >= 4/19/2023:
- See Section "Rules for Booster Dose", Bullet Point: "After completion of the Pfizer COVID-19 Series, Mixed Product COVID-19 Series, Moderna COVID-19 Series, Janssen COVID-19 Series or Novavax COVID-19 Series, and the execution date is >= 4/19/2023"
- if the execution date is >= 12/9/2022 and < 4/19/2023:
- and is >= 6 months of age, recommend a booster dose of COVID-19
- at
- recommended interval (8 weeks), recommended age (6 months) or on 12/9/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
- if the execution date is >= 10/12/2022 and < 12/9/2022:
- and is >= 5 years and < 12 years old,
- recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), recommended age (5 years) or on 10/12/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
- if the execution date is >= 9/2/2022:
- and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE
- if the execution date is >= 4/19/2023:
- the Pfizer COVID-19 Series,
Rules for an Additional Dose1
- _HIGH_RISK.
- and is >= 12 years old, recommend a booster dose of COVID-19
- at < 28 days after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 28 days required for an Additional Dose for immunocompromised patients or the minimum interval of 5 months required for a Booster Dose."
- at >= 28 days and < 5 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for a Booster Dose."
- at >= 5 months after series completion, then evaluate the shot as Valid.
- If a patient is >= 5 years old, completes a COVID-19 vaccine series via the Pfizer COVID-19 (5-17) 2-dose series and receives an additional shot of CVX 218, CVX 208, CVX 217, CVX 207, or CVX 213:
- at < 28 days after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 28 days required for an Additional Dose for immunocompromised patients or the minimum interval of 5 months required for a Booster Dose."
- at >= 28 days and < 5 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for a Booster Dose."
- at >= 5 months after series completion, then evaluate the shot as Valid.
Rules for Booster Dose2
Any of the FDA-Approved COVID-19 vaccines (except CVX 218) can be used for booster vaccination, regardless of the vaccine product used for primary vaccination. When a heterologous or “mix and match” booster dose is administered, the eligible population and dosing intervals are those of the vaccine used for primary vaccination.
Recommendation Rules for Booster Dose
- Recommend at the Vaccine Group Level (
- (at vaccine group level) at recommended interval (8 weeks), recommended age (12 years) or on 9/2/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
See “Rules for Booster Dose” for booster dose recommendations for the Moderna COVID-19 Series.
- the Janssen COVID-19 Series,
- If the execution date is >= 4/19/2023:
- See Section "Rules for Booster Dose", Bullet Point: "After completion of the Pfizer COVID-19 Series, Mixed Product COVID-19 Series, Moderna COVID-19 Series, Janssen COVID-19 Series or Novavax COVID-19 Series, and the execution date is >= 4/19/2023"
- Otherwise:
- and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), along with recommendation reason code BOOSTER_DOSE.
- and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
See “Rules for Booster Dose” for booster dose recommendations for the Janssen COVID-19 Series.
- If the execution date is >= 4/19/2023:
- the Novavax COVID-19 Series,
- If the execution date is >= 4/19/2023:
- See Section "Rules for Booster Dose", Bullet Point: "After completion of the Pfizer COVID-19 Series, Mixed Product COVID-19 Series, Moderna COVID-19 Series, Janssen COVID-19 Series or Novavax COVID-19 Series, and the execution date is >= 4/19/2023"
- Otherwise:
- and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks) or at recommended age (12 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE
- If the execution date is >= 4/19/2023:
- Recommended Age = 12 years
- Minimum Age = 12 years
- Recommended Interval
- After completion of Pfizer 2-dose series, Moderna 2-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA,
- .
a COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19
vaccine = 5 months- After completion of Janssen 1-dose series = 8 weeks
- After completion of Pfizer 2-dose series, Moderna 2-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA,
Evaluation Rules for Booster Dose
- Any of the FDA-Approved COVID-19 vaccines (except CVX 218) are allowed for the Booster Dose.
- Absolute Minimum Interval = 0 days
- If a patient completes a COVID-19 vaccine series via the Pfizer 2-dose series, Moderna 2-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a Booster Dose2 of CVX 208, CVX 217, CVX 207, CVX 212, or CVX 213:
- at < 28 days
vaccine,
- if the execution date is < 9/2/2022:
recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (12 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.
if the execution date is >= 10/12/2022:
and is >= 5 years and < 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), recommended age (5 years) or on 10/12/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
if the execution date is >= 9/2/2022:
and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), recommended age (12 years), or on 9/2/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
See “Rules for Booster Dose” for booster dose recommendations for the these series.
- if the execution date is < 9/2/2022:
- at < 28 days
Rules for an Additional Dose1
- If a patient completes a COVID-19 vaccine series via the Moderna COVID-19 Series or COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives an additional shot of CVX 207, CVX 208, CVX 211, CVX 212, CVX 213, CVX 217, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520:
- if the execution date is < 9/2/2022:
- at < 5 months after series completion, then evaluate the shot
- as Valid /
- SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of
- 5 months required for
- the 1st Booster Dose."
- at >=
- 5 months after series completion, then evaluate the shot as Valid.
- if the execution date is >= 9/2/2022 and < 4/19/2023:
- at < 8 weeks after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text:
- "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of
- 8 weeks required for
- the 1st Booster Dose."
- at >=
- 8 weeks after series completion, then evaluate the shot as Valid.
- if the execution date is < 9/2/2022:
If a patient completes
athe COVID-19 vaccine series via the
Janssen 1-dose series and receives a Booster Dose2 ofPfizer COVID-19 Series or the Mixed Product COVID-19 Series and receives an additional shot of CVX 207, CVX 208, CVX 211, CVX 213, CVX 217
, CVX 207, CVX 212, or CVX 213, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520:
if the patient is >= 5 years old and < 12 years old, or if the patient is >= 12 years old and the execution date is < 9/2/2022:
at <
5 months after series completion,
then evaluate the shot
as Valid /
SUPPLEMENTAL_TEXT; Descriptive Text:
"The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of
5 months required for
the 1st Booster Dose."
at >=
5 months after series completion, then evaluate the shot as Valid.
Rules for Extra Shots After Additional Dose1and/or Booster Dose2
- For patients that completed the Pfizer COVID-19 2-dose series, Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- For patients that completed the Pfizer COVID-19 Child (5-17) 2-dose Series,
- is < 5 years old, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- is > = 5 years old and < 12 years old and received an Additional Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- is > = 12 years old and received an Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- For patients that completed the Moderna COVID-19 2-dose series, Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- For patients that completed Janssen COVID-19 1-dose series and Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- For patients that completed either the 1) COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a 2) COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, Additional Dose and/or Booster Dose, any shots administered after the primary series is evaluated as Accepted/EXTRA_DOSE.
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
COVID-19 Vaccines
...
CVX Code
...
Name
...
Moderna COVID-19 Vaccine
...
208
...
Pfizer COVID-19 Vaccine
...
500
...
COVID-19 Non-US Vaccine, Product Unknown
...
501
...
COVID-19 IV Non-US Vaccine (QAZCOVID-IN)
...
502
...
COVID-19 IV Non-US Vaccine (COVAXIN)
...
503
...
COVID-19 LAV Non-US Vaccine (COVIVAC)
...
504
...
COVID-19 VVnr Non-US Vaccine (Sputnik Light)
...
505
...
COVID-19 VVnr Non-US Vaccine (Sputnik V)
...
506
...
COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology)
...
507
...
COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences)
...
508
...
COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
...
509
...
COVID-19 PS Non-US Vaccine (EpiVacCorona)
...
510
...
COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)
...
511
...
COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
...
Combination Vaccines that Include COVID-19
No combination vaccines exist, at this time, that include COVID-19 and count toward completion of the Pfizer COVID-19 2-dose series.
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
CVX Code Specific RulesCVX Code Absolute Minimum Age
CVX Code Absolute Maximum Age
Rule for CVX 213
Rules for COVID-19 Vaccines Not Authorized by FDA2The following set of rules apply to 1) COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO and, 2) COVID-19 Vaccines Not Authorized by FDA or WHO, but is an Active COVID-19 Vaccine Candidate as part of a U.S.-based Clinical Trial of a COVID-19 Vaccine.
Rules for Booster Dose2Any of the FDA-Approved COVID-19 vaccines (except CVX 218) can be used for booster vaccination, regardless of the vaccine product used for primary vaccination. When a heterologous or “mix and match” booster dose is administered, the eligible population and dosing intervals are those of the vaccine used for primary vaccination. Recommendation Rules for Booster Dose or Requirement for a Dose with a Bivalent Vaccine
Evaluation Rules for Booster Dose
Rules for Evaluation of Extra Shots After Additional Dose1 and/or Booster Doses and/or Needed Bivalent Dose2
|
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
COVID-19 Vaccines
CVX Code | Name | Absolute Minimum Age | Absolute Maximum Age | Counts towards U.S. Vaccination |
---|---|---|---|---|
207 | Moderna COVID-19 Vaccine | 0 days | Yes | |
208 | Pfizer COVID-19 Vaccine | 0 days | Yes | |
210 | AstraZeneca COVID-19 Vaccine | 0 days | Yes | |
211 | Novavax COVID-19 Vaccine | 0 days | Yes | |
212 | Janssen COVID-19 Vaccine | 0 days | Yes | |
213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | 0 days | Yes | |
217 | Pfizer COVID-19 Vaccine (>= 12 years) | 0 days | Yes | |
218 | Pfizer COVID-19 Vaccine | 0 days | 18 years - 1 day | Yes |
219 | Pfizer COVID-19 Vaccine | 0 days | 6 years - 1 day | Yes |
221 | Moderna COVID-19 Vaccine | 0 days | Yes | |
227 | Moderna COVID-19 Vaccine (Inactive) | 0 days | 13 years - 1 day | Yes |
228 | Moderna COVID-19 Vaccine | 0 days | 7 years - 1 day | Yes |
229 | Moderna COVID-19 Vaccine, Bivalent | 0 days | Yes | |
230 | Moderna, COVID-19 Vaccine, Bivalent Booster | 0 days | 7 years - 1 day | Yes |
300 | Pfizer COVID-19 Vaccine, Bivalent | 0 days | Yes | |
301 | Pfizer COVID-19 Vaccine, Bivalent | 0 days | 12 years - 1 day | Yes |
302 | Pfizer, COVID-19 Vaccine, Bivalent | 0 days | 6 years - 1 day | |
500 | COVID-19 Non-US Vaccine, Product Unknown | No | ||
501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | No | ||
502 | COVID-19 IV Non-US Vaccine (COVAXIN) | 0 days | Yes | |
503 | COVID-19 LAV Non-US Vaccine (COVIVAC) | No | ||
504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) | No | ||
505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) | No | ||
506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) | No | ||
507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences) | No | ||
508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | No | ||
509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) | No | ||
510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | 0 days | Yes | |
511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | 0 days | Yes | |
512 | COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | 18 years - 4 days | Yes | |
513 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | No | ||
514 | COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | No | ||
515 | COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | No | ||
516 | COVID-19 Inactivated Non-US Vaccine (Minhai Biotechnology Co, KCONVAC) | No | ||
517 | COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | No | ||
518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | No | ||
519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | 0 days | Yes | |
520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | 0 days | Yes | |
521 | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK | No |
Combination Vaccines that Include COVID-19
No combination vaccines exist, at this time, that include COVID-19 and count toward completion of the Pfizer COVID-19 2-dose series.
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
CVX Code Specific RulesCVX Code Absolute Minimum Age
CVX Code Absolute Maximum Age
Rule for CVX 218, CVX 219, CVX 227, CVX 228, CVX 229, CVX 230, CVX 301, CVX 302
Rule for Bivalent Vaccines (CVX 229, CVX 230, CVX 300, CVX 301, CVX 301, CVX 519, CVX 520)
Rule for CVX 213
Rules for COVID-19 Vaccines Not Authorized by FDA2The following set of rules apply to 1) COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO and, 2) COVID-19 Vaccines Not Authorized by FDA or WHO, but is an Active COVID-19 Vaccine Candidate as part of a U.S.-based Clinical Trial of a COVID-19 Vaccine.
|
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
|
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
Immunization Series and Selection Rules
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Name
Series Selection RulesThere are five series for this vaccine group: Pfizer COVID-19 Series, Moderna COVID-19 Series, Mixed Product COVID-19 Series, Janssen COVID-19 Series, and Novavax COVID-19 Series. The rules for determining which series applies are:
|
Immunization Series: Pfizer COVID-19 Series
The Pfizer COVID-19 Series is complete after 2 or 3 doses, depending on age (not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum Age | Minimum Age | Routine Age | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Pfizer COVID-19 Series | 0 days | 6 months | 6 months | N/A | 208, 217, 218, 219, 300, 301, 302 | 229, 230 |
2 | Pfizer COVID-19 Series | 0 days | 6 months | 6 months | N/A | 208, 217, 218, 219, 300, 301, 302 | 229, 230 |
3 | Pfizer COVID-19 Series | 0 days | 6 months | 6 months | N/A | 208, 217, 218, 219, 300, 301, 302 | 229, 230 |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Pfizer COVID-19 Series | 8 weeks - 4 days if dose 2 administered >= 4/19/2023 and dose 1 administered >= 5 years of age Otherwise, 17 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 21 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 21 days |
N/A |
Dose 2 to 3 | Pfizer COVID-19 Series | 8 weeks - 4 days | 8 weeks | 8 weeks | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series
Series Selection RulesThere are four series for this vaccine group: the Pfizer COVID-19 Child (5-17) 2-dose Series, Pfizer COVID-19 2-dose series, Moderna COVID-19 2-dose series, and Janssen COVID-19 1-dose series. The rules for determining which series applies are:
|
Immunization Series: Pfizer COVID-19 Child (5-17) 2-dose Series
...
Special Rules
Vaccine to Recommend
Skip Dose Rule
Rule for CVX 212 (Janssen COVID-19 vaccine)
|
Immunization Series: Moderna COVID-19 Series
The Moderna COVID-19 series is complete after 2 doses(not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Pfizer Moderna COVID-19 Child (5-17) 2-dose Series | 0 days | 6 months | 6 months | N/A | 218207, 208221, 217227, 207228, 213 229 | N/A |
2 | Pfizer COVID-19 Child (5-17) 2-dose Moderna COVID-19 Series | 0 days | 6 months | 6 months | N/A | 218207, 208221, 217227, 207228, 213 229 | N/A |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) | |||
---|---|---|---|---|---|---|---|---|
Dose 1 to 2 | Pfizer Moderna COVID-19 Child (5-17) 2-dose Series | 17 days | 21 days |
| 0 days if dose 2 administered < 10/25/2021 8 weeks - 4 days if dose 2 administered >= 4/19/2023 and dose 1 administered >= 6 years of age Otherwise, 24 days if dose 2 administered >= 10/25/2021 | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 6 years of age Otherwise, 28 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 administered >= 6 years of age Otherwise, 28 days | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Rule for CVX 212 (Janssen COVID-19 Vaccine)
Rule for CVX 207 (Moderna COVID-19 Vaccine) Administered < 18 years old
|
Immunization Series: Pfizer COVID-19 2-dose Series
...
Vaccine to Recommend
Rule for CVX 212 (Janssen COVID-19 vaccine)
|
Immunization Series: Mixed Product COVID-19 Series
The Mixed Product COVID-19 Series is complete after 2 or 3 doses, depending on age(not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Mixed Product COVID-19 Series | 1 | Pfizer COVID-19 2-dose Series | 18 years | 18 years | 18 years | 0 days | 6 months | 6 months | N/A | 207, 208, 211, 213, 217, 218, 219, 221, 227, 228, 300, 301, 302 | 229, 230 | |
2 | Mixed Product COVID-19 Series | 0 days | 6 months | 6 months | N/A | 2 | Pfizer COVID-19 2-dose Series | 18 years | 18 years | 207, 208 , 217, 213 | N/A | 18 years, 211, 213, 217, 218, 219, 221, 227, 228, 300, 301, 302 | 229, 230 |
3 | Mixed Product COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 208 | , 217, 207, 213N/A, 211, 213, 217, 218, 219, 221, 227, 228, 300, 301, 302 | 229, 230 |
Vaccine Dose Parameters - Minimum and Recommended Intervals
...
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Minimum Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Pfizer Mixed Product COVID-19 2-dose Series 0 days if dose 2 administered < 10/25/2021 17Series | 8 weeks - 4 days if dose 2 administered >= 104/ 25/2021 | 21 days | 21 days | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special RulesRule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))
Rule for CVX 212 (Janssen COVID-19 Vaccine)
|
Immunization Series: Moderna COVID-19 2-dose series
The Moderna COVID-19 2-dose series is complete after 2 doses.
Vaccine Dose Parameters - Minimum and Routine Ages
...
Dose
...
Series Name
...
Absolute Minimum
Age
...
Routine
Age
...
Latest Recommended Age (less than)
...
1
...
Moderna COVID-19 2-dose Series
...
18 years - 4 days
...
18 years
...
N/A
...
2
...
Moderna COVID-19 2-dose Series
...
N/A
Vaccine Dose Parameters - Minimum and Recommended Intervals
...
Doses
...
Series Name
...
Absolute Minimum Interval
...
Recommended Interval
...
Dose 1 to 2
...
Moderna COVID-19 2-dose Series
...
0 days if dose 2 administer < 10/25/2021
24 days if dose 2 administered >= 10/25/2021
...
28 days
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special RulesRule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))
Rule for CVX 212 (Janssen COVID-19 Vaccine)
|
Immunization Series: Janssen COVID-19 1-dose Series
19/2023 and dose 1 administered >= 5 years of age Otherwise:
| 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 28 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 28 days | N/A | ||
Dose 2 to 3 | Mixed Product COVID-19 Series | 8 weeks - 4 days | 8 weeks | 8 weeks | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Vaccine to Recommend
Skip Dose Rule
Rule for CVX 211 (Novavax COVID-19 vaccine)
Rule for CVX 212 (Janssen COVID-19 vaccine)
|
Immunization Series: Janssen COVID-19 Series
The Janssen COVID-19 Series is complete after 1 dose.
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Janssen COVID-19 Series | 0 days | 18 years | 18 years | N/A | 212 | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
|
Immunization Series: Novavax COVID-19 Series
The Novavax COVID-19 Series is complete after 2 doses (not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 |
Novavax COVID-19 |
Series |
12 years - 4 days |
12 years |
12 years | N/A |
211 | |||||
2 | Novavax COVID-19 Series | 12 years - 4 days | 12 years | 12 years | N/A |
...
borderColor | #CCFFFF |
---|---|
bgColor | #CCFFFF |
titleBGColor | #99FFFF |
borderStyle | solid |
Series Special Rules
...
211 |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Novavax COVID-19 Series | 17 days | 21 days | 21 days | 8 weeks |